UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of November 2025
Commission File Number: 001-39957
NEWCELX LTD.
(Translation of registrant’s name into
English)
The Circle 6
8058 Zurich, Switzerland
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form 20-F ☐ Form 40-F
CONTENTS
Press Release
On November 3, 2025, NewcelX
Ltd., a corporation incorporated under the laws of Switzerland (“NewCelX” or the “Company”), issued a press release
titled: “NewCelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd.” A
copy of this press release is furnished herewith as Exhibit 99.1.
Investor Presentation
On November 3, 2025, the Company made available an investor
presentation on its website. A copy of the investor presentation is furnished herewith as Exhibit 99.1.
EXHIBIT INDEX
Exhibit
Number |
|
Description of Document |
| 99.1 |
|
Press release titled: “NewCelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd.” |
| 99.2 |
|
Investor Presentation |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| |
NewcelX Ltd. |
| |
|
|
|
| Date: November 3, 2025 |
By: |
/s/ Ronen Twito |
| |
|
Name: |
Ronen Twito |
| |
|
Title: |
Chief Executive Officer |
